ORCA-010

News alerts, weekly reports and conference planners

Company:

ORCA Therap

Drug class:

CD80 modulator

Related drugs:

‹

GI-101 (1)

›

2years

First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. (clinicaltrials.gov)

P1/2, N=24, Active, not recruiting, Orca Therapeutics B.V. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Oct 2024

2 years ago

Enrollment closed • Trial completion date • Trial primary completion date • Oncolytic virus

PCA3 (Prostate cancer associated 3)

ORCA-010

over3years

First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. (clinicaltrials.gov)

P1/2, N=24, Recruiting, Orca Therapeutics B.V. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Nov 2023

over 3 years ago

Trial completion date • Trial primary completion date • Oncolytic virus

PCA3 (Prostate cancer associated 3)

ORCA-010

almost5years

Oncolytic adenovirus ORCA-010 activates pro-inflammatory myeloid cells and facilitates T cell recruitment and activation by PD-1 blockade in melanoma. (PubMed, Hum Gene Ther)

Observed increased rates of activated CD8 T cells, expressing CD69 and PD-1, were related to both increased CD8α cDC rates and M1/M2 shifts in tumor and spleen. In conclusion, the myeloid modulatory properties of ORCA-010 in melanoma, resulting in recruitment and activation of T cells, could enhance the antitumor efficacy of PD-1 blockade.

almost 5 years ago

Journal

PD-L1 (Programmed death ligand 1)

PD-L1-H

ORCA-010